Insulin resistance, glucose intolerance and diabetes mellitus in HIV-infected patients

Antiviral Therapy

Volumn 12, Issue 2, 2007, Pages 149-162

  Florescu, Diana ^a   Kotler, Donald P ^b,c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ABACAVIR; ANTIRETROVIRUS AGENT; BIGUANIDE; EFAVIRENZ; LOPINAVIR; METFORMIN; NEVIRAPINE; PIOGLITAZONE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CLINICAL PRACTICE; DIABETES MELLITUS; DRUG EFFECT; DRUG INHIBITION; GLUCOSE INTOLERANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MORBIDITY; MORTALITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW;

ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIABETES MELLITUS; GLUCOSE INTOLERANCE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; PREVALENCE;

EID: 34147183829     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic Abnormalities And Cardiovascular Disease Risk Factors In Adults With Human Immunodeficiency Virus Infection And Lipodystrophy. Clin Infect Dis 2001; 32:130-139.
2. Grinspoon S. Mechanisms and Strategies for Insulin Resistance in Acquired Immune Deficiency Syndrome. Clin Infect Dis 2003; 37 Suppl 2:S85-90.
3. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
4. Van der Valk M, Bisschop PH, Romjin JA, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001; 15:2093-2100.
5. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group Combination. Antiretroviral Therapy and the Risk of Myocardial Infarction. N Engl J Med 2003, 349:1993-2003.
6. Kahn CR. Insulin resistance, insulin insensitivity, and insulin unresponsiveness: a necessary distinction. Metabolism 1978; 27:1893-1902.
7. Campbell PJ, Mandarino LJ, Gerich JE. Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism 1988; 37:15-21.
8. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2002; 25:S5-S20.
9. Kahn R, Buse J, Ferrannini E, et al. The Metabolic Syndrome: Time for a Critical Appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28:2289-2304.
10. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-31.
11. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165:1179-1184.
12. Beregszaszi M, Dollfus C, Levine M, et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 2005; 40:161-168.
13. Hommes MJ, Romijn JA, Endert E, Eeftinck Schattenkerk JK, Sauerwein HP. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40:651-656.
14. Gan SK, Samaras K, Thompson CH, et al. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51:3163-3169.
15. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated hyperglycaemia. Lancet 1997; 350:713-714.
16. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of protease inhibitor. Ann Intern Med 1997; 127:948.
17. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997; 127:947.
18. US Food and Drug Administration. Protease inhibitors may increase blood glucose in HIV patients. FDA Med Bull 1997; 27:2.
19. Hadigan C, Miller K, Corcoran C, et al. Fasting Hyperinsulinemia and Changes in Regional Body Composition in Human Immunodeficiency Virus-Infected Women. J Clin Endocrinol Metab 1999; 84:1932-1037.
20. Hadigan C, Corcoran C, Stanley T, et al. Fasting Hyperinsulinemia in Human Immunodeficiency Virus-Infected Men: Relationship to Body Composition, Gonadal Function, and Protease Inhibitor Use. J Clin Endocrinol Metab 2000; 85: 35-41.
21. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
22. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003; 2:812-822.
23. Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004; 4:763-777.
24. Muthumani K, Hwang DS, Desai BM, et al. HIV-1 Vpr induces apoptosis through caspase 9 in T cells and peripheral blood mononuclear cells. J Biol Chem 2002; 277:37820-37831.
25. Muthumani K, Choo AY, Hwang, D.S., et al. Mechanism of HIV-1 viral protein R-induced apoptosis. Biochem Biophys Res Commun 2003; 304:583-592.
26. Arnoult D, Petit F, Lelievre JD, et al. Mitochondria in HIV-1-induced apoptosis. Biochem Biophys Res Commun 2003; 304:561-574.
27. Brenner C, Kroemer G. The mitochondriotoxic domain of Vpr determines HIV-1 virulence. J Clin Invest 2003; 111:1455-1457.
28. Roumier T, Castedo M, Perfettini JL, et al. Mitochondrion- dependent caspase activation by the HIV-1 envelope. Biochem Pharmacol 2003; 66:1321-1329.
29. Mallon PW, Unemori P, Sedwell R, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis 2005; 191:1686-1696.
30. Birkus G, Hajek M, Kramata P, Votruba I, Holy A, Otova B. Tenofovir diphosphate is a poor substrate and a weak inhibitor of rat DNA polymerases α, δ, and ε. Antimicrob Agents Chemother 2002; 46:1610-1613.
31. Cihlar T, Birkus G, Greenwalt DE, Hitchcock MJ. Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors. Antivir Res 2002; 54:37-45.
32. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005; 87:65-71.
33. Lagathu C, Bastard JP, Auclair M, et al. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro. Antivir Ther 2004; 9:911-920.
34. Roche R, Poizot-Martin I, Yazidi CM, et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 2002; 16:13-20.
35. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-2136.
36. Ranade K, Parker R, Ploughman L, et al. A Single Nucleotide Polymorphism in the Resistin Gene Is Associated with Adverse Metabolic Changes on HAART: An Exploratory Pharmacogenetic Association Study of A5005S, the Metabolic Sub-study of ACTG 384. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, USA. Abstract 763.
37. Morino K, Petersen KF, Dufour S, et al. Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 2005; 115:3587-3593.
38. Johnson JA, Albu JA, Engelson ES, et al. Increased proinflammatory cytokine activity in HIV-infected subjects with lipodystrophy. Am J Physiol Endocrinol Metab 2004; 286:E261-E271.
39. Hadigan C, Borgonha S, Rabe J, Young V, Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 2002; 51:1143-1147.
40. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 2003; 77:490-494.
41. Arner P. Insulin resistance in type 2 diabetes: role of fatty acids. Diabetes Metab Res Rev 2002; 18 Suppl 2:S5-S9.
42. Frayn KN, Williams CM, Arner P. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases? Clin Sci (Lond) 1996; 90:243-253.
43. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998; 14:263-283.
44. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-1052.
45. Vigouroux C, Gharakhanian S, Salhi Y, et al. Diabetes, insulin resistance and dyslipidemia in lipodystrophic HIV-infected patient on highly active antiretroviral therapy (HAART). Diabetes Metab 1999; 25:225-232.
46. Meininger G, Hadigan C, Laposata M, et al. Elevated concentrations of free fatty acids are associated with increased insulin response to standard glucose challenge in HIV-infected subjects with fat redistribution. Metabolism 2002; 51:260-266.
47. Joly V, Flandre P, Meiffredy V, et al. Assessment of lipodystrophy in patients previously exposed to AZT, ddI, ddC, but naive for d4T and protease inhibitors, and randomized between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR Trial). 8th Conference on Retroviruses and Opportunistic Infections. 4-8 February 2001, Chicago, USA. Abstract 539.
48. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1983.
49. Lo JC, Kazemi MR, Hsue PY, et al. The relationship between nucleoside analogue treatment duration, insulin resistance, and fasting arterialized lactate level in patients with HIV infection. Clin Infect Dis 2005; 41:1335-1340.
50. Hadigan C. Insulin resistance among HIV-infected patients: unraveling the mechanism. Clin Infect Dis 2005; 41:1341-1342.
51. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving protease inhibitors. AIDS 1998; 12:F51-F58.
52. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defiv Syndr 2000; 23:35-43.
53. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000; 275:20251-20254.
54. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15:F11-F18.
55. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
56. Noor M, Flint OP, Parker RA, Maa J, Witek J, Hodder SL. Evaluation of insulin sensitivity in healthy volunteers treated with low-dose ritonavir combined with atazanavir (ATV/RTV) or lopinavir (LPV/RTV): a prospective, randomized study using hyperinsulinaemic, euglycaemic clamp and oral glucose tolerance testing. Antiv Ther 2005; 10 Suppl 3:L11 (Abstract 16).
57. Lee G, Rao MN, Schwarz JM, Aweeka FT, Grunfeld C. A single dose of amprenavir does not induce insulin resistance in healthy normal volunteers. Antiv Ther 2005; 10 (Suppl 3):L11 (Abstract 15).
58. Noor MA, Parker RA, O'Mara E, et al. The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS 2004; 18:2137-2144.
59. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
60. Dube MP, Qian D, Edmondson-Melancon H, et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin Infect Dis. 2002; 35:475-481.
61. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50:1378-1388.
62. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antivir Res 2000; 47:121-129.
63. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17:2437-2444.
64. Murata H, Hruz PW, Mueckler M. Indinavir inhibits the glucose transporter isoform Glut4 at physiologic concentrations. AIDS 2002; 16:859-863.
65. Vernochet C, Azoulay S, Duval D, Guedj R, Ailhaud G, Dani C. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. AIDS 2003; 17:2177-2180.
66. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000; 275:41325-41332.
67. Janneh O, Hoggard PG, Tjia JF, et al. Intracellular disposition and metabolic effects of zidovudine, stavudine and four protease inhibitors in cultured adipocytes. Antivir Ther 2003; 8:417-426.
68. Estaquier J, Lelievre JD, Petit F, et al. Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(C) T-cell death. J Virol 2002; 76:5966-5973.
69. Pilon AA, Lum JJ, Sanchez-Dardon J, Phenix BN, Douglas R, Badley AD. Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor. Antimicrob Agents Chemother 2002; 46:2687-2691.
70. Phenix BN, Lum JJ, Nie Z, Sanchez-Dardon J, Badley AD. Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 2001; 98:1078-1085.
71. Miro O, Villarroya J, Garrabou G, et al. In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosis. Antivir Ther 2005; 10:945-951.
72. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000; 95:3191-3198.
73. Christeff N, Melchior JC, de Truchis P, Perronne C, Gougeon ML. Increased serum interferon alpha in HIV-1 associated lipodystrophy syndrome. Eur J Clin Invest 2002; 32:43-50.
74. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferatoractivated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762.
75. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related ro lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511.
76. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000; 25:312-321.
77. Domingo P, Vidal F, Domingo JC, et al. Tumour necrosis factor α in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis. Eur J Clin Invest 2005; 35:771-780.
78. Domingo P, Matias-Guiu X, Pujol RM, et al. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy. AIDS 1999; 13:2261-2267.
79. Domingo P, Matias-Guiu X, Pujol RM, et al. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly-active antiretroviral therapy-associated lipodystrophy. J Infect Dis 2001; 184:1197-1201.
80. Shahmanesh M, Das S, Stolinski M, et al. Insulin Resistance and Apolipoprotein B Kinetics: A Comparison of Protease Inhibitor-, Efavirenz-, or Nevirapine-containing Antiretroviral Regimens. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, USA. Abstract 704.
81. Mynarcik DC, Combs T, McNurlan MA, et al. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr 2002; 31:514-520.
82. Vernochet C, Azoulay S, Duval D, et al. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. J Biol Chem 2004; 280:2238-2243.
83. Lee GA, Mafong DD, Noor MA, et al. HIV protease inhibitors increase adiponectin levels in HIV-negative men. J Acquir Immune Defic Syndr 2004; 36:645-647.
84. Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect 2005; 50:331-337.
85. de Larranaga GF, Wingeyer SD, Puga LM, Alonso BS, Benetucci JA. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV-HCV-coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 2006; 25:98-103.
86. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS. The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 2003; 33:577-584.
87. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27:245-250.
88. Singh AB, Hsia S, Alaupovic P, et al. The effects of varying doses of T on insulin sensitivity, plasma lipids, apolipoproteins, and C-reactive protein in healthy young men. J Clin Endocrinol Metab 2002; 87:136-143.
89. Bhasin S. Effects of Testosterone Administration on Fat Distribution, Insulin Sensitivity, and Atherosclerosis Progression. Clin Infect Dis 2003; 37:S142-S149.
90. Collins E, Wagner C, Walmsey S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader 2000; 10:546-550.
91. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary disease with protease inhibitors. Lancet 1998; 351:1328-1329.
92. Klein D; Hurley LB; Quesenberry CP; Sidney S. Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV-1 Infection? J Acquir Immune Defic Syndr 2002; 30:471-477.
93. Bozzette SA, Ake C, Carpenter A, et al. Cardio-and Cerebrovascular Outcomes with Changing Process of Anti-HIV Therapy in 36,766 US Veterans. 9th Conference on Retroviruses and Opportunistic Infections. 24-28 February 2002, Seattle, USA. Absract LB9.
94. Currier J, Boyd F, Burtcel B, et al. Accelerated atherosclerosis in men infected with HIV. Antivir Ther 2001; 6 Suppl 4:36. Abstract 49.
95. Mary-Krause M, Cotte L, Partisani M, Simon A, Costagliola D. Impact of Treatment with Protease Inhibitor (PI) on Myocardial Infarction (MI) Occurrence in HIV-infected Men. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. February 4-8, 2001, Chicago, USA. Abstract 657.
96. El-Sadr W, Reiss P, De Wit S, et al. Relationship between Prolonged Exposure to Combination ART and Myocardial Infarction: Effect of Sex, Age, and Lipid Changes. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, USA. Abstract 42.
97. Friis-Møller N, Reiss P, El-Sadr W, et al. Exposure to PI and NNRTI and Risk of Myocardial Infarction: Results from the D:A:D Study. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, USA. Oral Abstract 144.
98. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997; 349:462-466.
99. Abdelmouttaleb I, Danchin N, Hardo C, et al. C-Reactive protein and coronary artery disease: additional evidence of the implication of an inflammatory process in acute coronary syndromes. Am Heart J 1999; 137:346-351.
100. Haidari M, Javadi E, Sadeghi B, Hajilooi M, Ghanbili J. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem 2001; 34:309-315.
101. Heinrich J, Schulte H, Schönfeld R, Köhler E, Assmann G. Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb Haemostas 1995; 73:374-378.
102. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-126
103. Playford DA, Watts GF. Special article: non-invasive measurement of endothelial function. Clin Exp Pharmacol Physiol 1998; 25:640-643
104. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
105. Nolan D, Watts GF, Herrmann SE, French MA, John M, Mallal S. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM 2003; 96:825-832.
106. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42:1325-1332.
107. Ardigo D, Franzini L, Valtuena S, Monti LD, Reaven GM, Zavaroni I. Relation of plasma insulin levels to forearm flow-mediated dilatation in healthy volunteers. Am J Cardiol 2006; 97:1250-1254.
108. Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol 2006; 5:9.
109. Hadigan C, Meigs JB, Rabe J, et al. Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001; 86:939-943.
110. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19:927-933.
111. Stephan C, Carlebach A, Haberl A, et al. Long Term HIV Infection as an Independent Risk Factor for Early Atherosclerosis. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, USA. Abstract 738.
112. Schambelan M, Benson CA, Carr A, et al. Management of Metabolic Complications Associated With Antiretroviral Therapy for HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel. J Acquir Immune Defic Syndr 2002; 31:257-275.
113. American Diabetes Association. Standards of medical care of patients with diabetes mellitus. Diabetes Care 2000; 23 Suppl 1:S32-S42.
114. Brambilla AM, Novati R, Calori G, et al. Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. AIDS 2003; 17:1993-1995.
115. Shlay JC, Visnegarwala F, Bartsch G, et al. Body Composition and Metabolic Changes in Antiretroviral-Naive Patients Randomized to Didanosine and Stavudine vs. Abacavir and Lamivudine. J Acquir Immune Defic Syndr 2005; 38:147-155.
116. Drechsler H, Powderly WG. Switching Effective Antiretroviral Therapy: A Review. Clin Infect Dis 2002; 35:1219-1230.
117. Martinez E, Conget I, Lozano R, et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 1999; 13:805-810.
118. Gatell JM, Conget I, Lozano R, et al. One year effects of switching from HIV-1 protease inhibitors to nevirapine on metabolic abnormalities. Antivir Ther 1999; 4 Suppl 2:Abstract 40.
119. Gharakhanian S, Salhi Y, Adda N, et al. Identification of fat redistribution/metabolic abnormalities in a cohort treated by 2 NRTIs + 1 PI and absence of significant modification following PI substitution with efavirenz [abstract 46]. In Programs and Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco), 2000. Alexandria, VA: Foundation for Retroviruses and Human Health.
120. Martinez E, Romeu J, Garcia-Viejo A, et al. An open randomized study on the replacement of HIV-1 protease inhibitors by efavirenz in chronically suppressed HIV-1-infected patients with lipodystrophy [abstract 668]. In: Programs and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections (Chicago), 2001. Alexandria, VA: Foundation for Retroviruses and Human Health.
121. Moyle GJ, Baldwin C, Mandalia S, et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single arm observational cohort [letter]. J Acquir Immune Defic Syndr 2001; 28:399-401.
122. Estrada V, de Villar N, Larrad MT, Lopez AG, Fernandez C, Serrano-Rios M. Long-term metabolic consequences of switiching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 2002; 35:69-76.
123. Tebas P, Yarasheski K, Henry K, et al. Evolution of multiple metabolic parameters after the switch of protease inhibitors to nevirapine [abstract ThPpB1485]. In: Programs and abstracts of the 13th International Conference on AIDS (Durban, South Africa), 2000. Rome: International AIDS Society.
124. Tebas P, Yarasheski K, Henry K, et al. Evaluation of the virological and metabolic effects of switching protease inhibitor combination antiretroviral therapy to nevirapine-based therapy for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20:589-594.
125. Rozenbaum W, Delfraissy JF, Bentata M, et al. Metabolic and clinical evaluation of lipodystrophy 48 weeks after switching from two nucleoside reverse transcriptase inhibitors/protease inhibitor to two nucleoside reverse transcriptase inhibitors/abacavir (French Substudy, CNA30017). Antivir Ther 2000; 5 Suppl 5:Abstract P89.
126. Walli R, Michl G, Bogner JR, Goebel FD. Improvement of HAART-associated insulin resistance and dysplipidemia after replacement of protease inhibitors with abacavir. Eur J Med Res 2001; 6:413-421.
127. Bickel M, Rickerts V, Jacobi V, et al. Evolution of fasting metabolic parameters and fat distribution after switching protease inhibitor in the PROTRA study. Antivir Ther 2000; 5 Suppl 5:Abstract P90.
128. Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label multicenter study. AIDS 2001; 15:1811-1822.
129. Fisac C, Fumero E, Crespo M, et al. A randomized trial of metabolic and body composition changes in patients switching from PI-containing regimens to abacavir, efavirenz, nevirapine [abstract 699]. In: Programs and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections (Seattle), 2002. Alexandria, VA: Foundation for Retroviruses and Human Health.
130. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy [abstract 52]. In: Programs and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections (San Francisco), 2000. Alexandria, VA: Foundation for Retroviruses and Human Health.
131. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215.
132. Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. N Engl J Med 2003; 349:1036-1046.
133. Calza L, Manfredi R, Colangeli V, et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 2005; 19:1051-1058.
134. Martin A, Smith D, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
135. Driscoll SD, Meininger GE, Lareau MT, et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 2004; 18:465-473.
136. Gavrila A, Tsiodras S, Doweiko J, et al. Exercise and vitamin E intake are independently associated with metabolic abnormalities in human immunodeficiency virus-positive subjects: a cross-sectional study. Clin Infect Dis 2003; 36:1593-1601
137. Yarasheski KE, Tebas P, Stanerson B, et al. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. J Appl Physiol 2001; 90:133-138.
138. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000; 284:472-477.
139. Saint-Marc T, Touraine JL. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 1999; 13:1000-1002.
140. Worth L, Elliott J, Anderson J, Sasadeusz J, Street A, Lewin S. A cautionary tale: fatal lactic acidosis complicating nucleoside analogue and metformin therapy. Clin Infect Dis 2003; 37:315-316.
141. Schwartz S, Raskin P, Fonseca V, Graveline JF. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998; 338:861-866.
142. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338:867-872.
143. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR-γ 2, a lipid-activated transcription factor. Cell 1994; 79:1147-1156.
144. Arioglu E, Duncan-Morin J, Sebring N, et al. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes. Ann Intern Med 2000; 133:263-274.
145. Hadigan C, Yawetz S, Thomas A, Havers F, Sax P, Grinspoon S. Metabolic Effects of Rosiglitazone in HIV Lipodystrophy: A Randomized, Controlled Trial. Ann Intern Med 2004; 140:786-794.
146. Carr A, Workman C, Carey D, et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004; 363:429-438.
147. Sutinen J, Hakkinen AM, Westerbacka J, et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy- - a randomized double-blind placebo-controlled study. Antivir Ther 2003; 8:199-207.
148. Yki-Jarvinen H, Sutinen J, Silveira A, et al. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscler Thromb Vasc Biol 2003; 23:688-694.
149. Grundy SM, Hansen B, Smith SC Jr, et al. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Arterioscler Thromb Vasc Biol 2004; 24:e19-e24.